Literature DB >> 27921220

Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals.

Josué Pérez-Santiago1, Michelli F De Oliveira2, Susanna R Var3, Tyler R C Day4, Steven P Woods5, Sara Gianella2, Sanjay R Mehta2,6.   

Abstract

Cell-free mitochondrial DNA (mtDNA) is a highly immunogenic molecule that is associated with several inflammatory conditions and with neurocognitive impairment during untreated HIV infection. Here, we investigate how cell-free mtDNA in cerebrospinal fluid (CSF) is associated with inflammation, neuronal damage, and neurocognitive functioning in the context of long-term suppressive antiretroviral therapy (ART). We quantified the levels of cell-free mtDNA in the CSF from 41 HIV-infected individuals with completely suppressed HIV RNA levels in blood plasma (<50 copies/mL) by droplet digital PCR. We measured soluble CD14, soluble CD163, interferon γ-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor-α (TNF-α), neopterin, and neurofilament light chain (NFL) by immunoassays in CSF supernatant or blood plasma. Higher levels of mtDNA in CSF were associated with higher levels of MCP-1 (r = 0.56, p < 0.01) in CSF and TNF-α (r = 0.43, p < 0.01) and IL-8 (r = 0.44, p < 0.01) in blood plasma. Subjects with a previous diagnosis of AIDS showed significantly higher levels of mtDNA (p < 0.01) than subjects without AIDS. The associations between mtDNA and MCP-1 in CSF and TNF-α in blood remained significant after adjusting for previous diagnosis of AIDS (p < 0.01). Additionally, higher levels of mtDNA were associated with a lower CD4 nadir (r = -0.41, p < 0.01) and lower current CD4% (r = -0.34, p = 0.03). Paradoxically, higher levels of mtDNA in CSF were significantly associated with better neurocognitive performance (r = 0.43, p = 0.02) and with less neuronal damage (i.e. lower NFL). Higher cell-free mtDNA is associated with inflammation during treated HIV infection, but the impact on neurocognitive functioning and neuronal damage remains unclear and may differ in the setting of suppressive ART.

Entities:  

Keywords:  Inflammation; Neurocognitive performance; Neurodegeneration; ddPCR; mtDNA

Mesh:

Substances:

Year:  2016        PMID: 27921220      PMCID: PMC5538255          DOI: 10.1007/s13365-016-0497-5

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  24 in total

Review 1.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

2.  T cell activation and disease severity in HIV infection.

Authors:  M Mahalingam; M Peakman; E T Davies; A Pozniak; T J McManus; D Vergani
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

3.  Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients.

Authors:  M Bofill; A Mocroft; M Lipman; E Medina; N J Borthwick; C A Sabin; A Timms; M Winter; L Baptista; M A Johnson; C A Lee; A N Phillips; G Janossy
Journal:  AIDS       Date:  1996-07       Impact factor: 4.177

4.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

5.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

6.  Mitochondrial injury and cognitive function in HIV infection and methamphetamine use.

Authors:  Susanna R Var; Tyler R C Day; Andrej Vitomirov; Davey M Smith; Virawudh Soontornniyomkij; David J Moore; Cristian L Achim; Sanjay R Mehta; Josué Pérez-Santiago
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

7.  Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy.

Authors:  Kristine M Erlandson; Amanda A Allshouse; Catherine M Jankowski; Eric J Lee; Kevin M Rufner; Brent E Palmer; Cara C Wilson; Samantha MaWhinney; Wendy M Kohrt; Thomas B Campbell
Journal:  J Infect Dis       Date:  2013-04-04       Impact factor: 5.226

Review 8.  HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities.

Authors:  Jeymohan Joseph; Deborah A Colosi; Vasudev R Rao
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  High-throughput droplet digital PCR system for absolute quantitation of DNA copy number.

Authors:  Benjamin J Hindson; Kevin D Ness; Donald A Masquelier; Phillip Belgrader; Nicholas J Heredia; Anthony J Makarewicz; Isaac J Bright; Michael Y Lucero; Amy L Hiddessen; Tina C Legler; Tyler K Kitano; Michael R Hodel; Jonathan F Petersen; Paul W Wyatt; Erin R Steenblock; Pallavi H Shah; Luc J Bousse; Camille B Troup; Jeffrey C Mellen; Dean K Wittmann; Nicholas G Erndt; Thomas H Cauley; Ryan T Koehler; Austin P So; Simant Dube; Klint A Rose; Luz Montesclaros; Shenglong Wang; David P Stumbo; Shawn P Hodges; Steven Romine; Fred P Milanovich; Helen E White; John F Regan; George A Karlin-Neumann; Christopher M Hindson; Serge Saxonov; Bill W Colston
Journal:  Anal Chem       Date:  2011-10-28       Impact factor: 6.986

10.  Increased inflammation but similar physical composition and function in older-aged, HIV-1 infected subjects.

Authors:  Mark A Wallet; Thomas W Buford; Anna-Maria Joseph; Madhuri Sankuratri; Christiaan Leeuwenburgh; Marco Pahor; Todd Manini; John W Sleasman; Maureen M Goodenow
Journal:  BMC Immunol       Date:  2015-07-24       Impact factor: 3.615

View more
  6 in total

1.  Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluid.

Authors:  Dipesh Solanky; Jerel A Fields; Jennifer E Iudicello; Ronald J Ellis; Donald Franklin; David B Clifford; Benjamin B Gelman; Christina M Marra; Susan Morgello; Leah H Rubin; Igor Grant; Robert K Heaton; Scott L Letendre; Sanjay R Mehta
Journal:  J Neurovirol       Date:  2022-02-14       Impact factor: 3.739

2.  Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.

Authors:  Debjani Guha; Shibani S Mukerji; Sukrutha Chettimada; Vikas Misra; David R Lorenz; Susan Morgello; Dana Gabuzda
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

3.  HIV-Associated Neurocognitive Impairment in the Modern ART Era: Are We Close to Discovering Reliable Biomarkers in the Setting of Virological Suppression?

Authors:  Alessandra Bandera; Lucia Taramasso; Giorgio Bozzi; Antonio Muscatello; Jake A Robinson; Tricia H Burdo; Andrea Gori
Journal:  Front Aging Neurosci       Date:  2019-08-02       Impact factor: 5.750

4.  Circulating cell-free mitochondrial DNA levels in Parkinson's disease are influenced by treatment.

Authors:  Hannah Lowes; Angela Pyle; Mauro Santibanez-Koref; Gavin Hudson
Journal:  Mol Neurodegener       Date:  2020-02-18       Impact factor: 14.195

5.  Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease.

Authors:  Hannah Lowes; Marzena Kurzawa-Akanbi; Angela Pyle; Gavin Hudson
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

6.  Long-term treated HIV infection is associated with platelet mitochondrial dysfunction.

Authors:  Wouter A van der Heijden; Lisa van de Wijer; Martin Jaeger; Karin Grintjes; Mihai G Netea; Rolf T Urbanus; Reinout van Crevel; Lambertus P van den Heuvel; Maaike Brink; Richard J Rodenburg; Philip G de Groot; Andre J van der Ven; Quirijn de Mast
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.